Nevertheless, it is already known that, like CD4+ Tregs, CD8+ Tregs expand in response to IL-2 treatment, as we previously showed in a clinical trial using low-dose IL-2 in hepatitis C virus-induced vasculitis (32) and type 1 diabetes (33). This evidence concerns the gene IL2 and vasculitis.